Globus Medical, Inc.

NYSE:GMED Rapporto sulle azioni

Cap. di mercato: US$9.8b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Globus Medical Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Dan Scavilla

Amministratore delegato

US$4.6m

Compenso totale

Percentuale dello stipendio del CEO10.2%
Mandato del CEO2.3yrs
Proprietà del CEOn/a
Durata media del management5.3yrs
Durata media del Consiglio di amministrazione5.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Globus Medical: A Post Acquisition Analysis

Aug 26

Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors

Jun 28
Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors

An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Apr 08
An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly

Mar 20
Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly

Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock

Feb 27

Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?

Feb 09
Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?

Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings

Jan 17
Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings

Globus Medical: Merger Overhang Lingering

Nov 27

Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?

Nov 14
Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?

Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?

Oct 27
Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?

Globus Medical: Almost Having My Back

Sep 13

Globus Medical: Slightly Too Pricey Right Now

Aug 07

Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy

Jul 18

Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?

Jul 11
Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?

Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching

Jun 18
Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching

Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

Apr 09
Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?

Mar 22
What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?

Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?

Feb 24
Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?

Globus Medical Q4 2022 Earnings Preview

Feb 20

Globus Medical: An Impressive Long-Term Revenue Growth Play

Jan 08

Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

Dec 22
Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends

Dec 01
Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends

Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line

Nov 08

A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)

Oct 15
A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)

Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact

Sep 02

Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

Sep 02
Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?

Aug 11
Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?

Globus Medical: Low Rates Sensitivity, Seeking 26% Return Objective

Jun 05

Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital

May 24
Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital

Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

May 06
Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dan Scavilla rispetto agli utili di Globus Medical?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

US$41m

Mar 31 2024n/an/a

US$67m

Dec 31 2023US$5mUS$464k

US$123m

Sep 30 2023n/an/a

US$158m

Jun 30 2023n/an/a

US$204m

Mar 31 2023n/an/a

US$201m

Dec 31 2022US$4mUS$437k

US$190m

Sep 30 2022n/an/a

US$155m

Jun 30 2022n/an/a

US$155m

Mar 31 2022n/an/a

US$142m

Dec 31 2021US$2mUS$396k

US$149m

Sep 30 2021n/an/a

US$187m

Jun 30 2021n/an/a

US$184m

Mar 31 2021n/an/a

US$122m

Dec 31 2020US$2mUS$384k

US$102m

Sep 30 2020n/an/a

US$95m

Jun 30 2020n/an/a

US$89m

Mar 31 2020n/an/a

US$148m

Dec 31 2019US$2mUS$366k

US$155m

Sep 30 2019n/an/a

US$146m

Jun 30 2019n/an/a

US$143m

Mar 31 2019n/an/a

US$150m

Dec 31 2018US$2mUS$355k

US$156m

Sep 30 2018n/an/a

US$144m

Jun 30 2018n/an/a

US$134m

Mar 31 2018n/an/a

US$118m

Dec 31 2017US$1mUS$345k

US$107m

Compensazione vs Mercato: La retribuzione totale di Dan ($USD 4.56M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 8.39M ).

Compensazione vs guadagni: La retribuzione di Dan è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Dan Scavilla (59 yo)

2.3yrs

Mandato

US$4,564,374

Compensazione

Mr. Daniel T. Scavilla, also known as Dan, serves as President and Chief Executive Officer at Globus Medical, Inc. since April 21, 2022 and serves as its Director since April 2022. He had been Executive Vi...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
David Paul
Co-Founder & Executive Chairman21.6yrsUS$3.22m16.44%
$ 1.6b
Daniel Scavilla
President2.3yrsUS$4.56mNessun dato
Keith Pfeil
CFO & COO5yrsUS$2.06m0%
$ 0
Kelly Huller
Senior VP5.7yrsUS$1.64m0%
$ 0
Brian Kearns
Senior Vice President of Business Development & Investor Relationsno dataNessun datoNessun dato

5.3yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di GMED è esperto e expertise (durata media dell'incarico 5.3 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
David Paul
Co-Founder & Executive Chairman21.6yrsUS$3.22m16.44%
$ 1.6b
Daniel Scavilla
President2.3yrsUS$4.56mNessun dato
Ann Rhoads
Independent Director13.1yrsUS$490.69k0.017%
$ 1.6m
John DeFord
Independent Directorless than a yearUS$276.27k0.011%
$ 1.1m
Stephen Zarrilli
Independent Director5.3yrsUS$470.69k0%
$ 0
James Tobin
Independent Director9yrsUS$478.19k0%
$ 0
Daniel Wolterman
Independent Directorless than a yearUS$278.15k0.018%
$ 1.7m
Robert Douglas
Independent Director4.7yrsUS$470.69k0.0015%
$ 144.4k
David Davidar
Independent Director21.4yrsUS$468.19k0.57%
$ 55.6m
Leslie Norwalk
Independent Directorless than a yearUS$278.77k0.012%
$ 1.2m
Daniel Lemaitre
Independent Director13.3yrsUS$478.19k0%
$ 0

5.3yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GMED sono considerati esperti (durata media dell'incarico 5.3 anni).